Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer

Phase 1

Terminated

Brief Summary: The primary objective of the Phase II portion of this study is to assess the efficacy of KRN330 in combination with irinotecan after first-line or adjuvant FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin)/CapOx (capecitabine and oxaliplatin) treatment failure in patients with metastatic colorectal cancer.

Detailed Description: Phase II portion is an open-label, single arm study. Based on the results of the Phase I portion, weekly KRN330 (0.5 mg/kg) and biweekly irinotecan (180 mg/m2) will be used in the Phase II portion. To be eligible for the Phase II portion, a patient will have recurred or progressed within 6 months of the last cycle of FOLFOX/CapOx +/- bevacizumab (first-line or adjuvant regimen for metastatic colorectal cancer). Patients will continue the treatment until disease progression.

Per protocol, the decision was made to terminate the study based on interim analysis results. The Response Rate in Phase II did not meet the protocol-specified RR of 15% when 0.5 mg/kg KRN330 was administered weekly in combination with irinotecan(180 mg/m2)biweekly.

Recruitment & Eligibility

Inclusion Criteria

Have histologically confirmed colorectal cancer that is metastatic with measurable disease.
For the Phase II portion: Have recurred or progressed within 6 months of the last cycle of FOLFOX +/- bevacizumab first-line or adjuvant regimen for metastatic colorectal cancer. Note: Those who had initiated FOLFOX/CapOx but stopped oxaliplatin because of intolerable toxicity are also eligible.
At least 4 weeks have elapsed since the last chemotherapy, radiotherapy, immunotherapy, or biologic therapy prior to enrollment (except at least 6 weeks in the case of nitrosourea and mitomycin).
Have not received any other investigational agents within 4 weeks of study entry and have fully recovered from any adverse event due to prior therapy.
At least 4 weeks have elapsed since any major surgery.
Have ECOG performance status of 0, 1, or 2.
Have adequate bone marrow and organ function

Exclusion Criteria

Have an active, uncontrolled infection.
Have known HIV positive status.
Have known or suspected cerebral metastasis.
Have had a myocardial infarction (MI) or cerebrovascular accident (CVA) within the last 6 months; or meet the criteria for AHA class III or IV congestive heart failure (CHF).
Have a medical condition requiring chronic use of high-dose corticosteroids or other chronic immunosuppressive therapy (e.g. methotrexate, azathioprine).
Have a history of greater than or equal to Grade 2 allergic reaction or hypersensitivity following exposure to humanized or human monoclonal antibodies (but not chimeric antibodies).
Pregnant or breastfeeding women and male or female patients who do not agree to use effective contraceptive method(s) during the study.

Arm && Interventions

Group	Intervention	Description
KRN330 + Irinotecan	KRN330	open label, single arm
KRN330 + Irinotecan	Irinotecan	open label, single arm

Primary Outcome Measures

Name	Time	Method
Number of Participants With Serious and Other (Non-Serious) Adverse Events According to the CTCAE v.3.0	Until disease progression, death, or withdrawal post initial KRN330 treatment, assessed up to 100 months

Secondary Outcome Measures

Name	Time	Method

Locations (12): Emory University - Winship Cancer Institute
🇺🇸
Atlanta, Georgia, United States
Greater Baltimore Medical Center
🇺🇸
Baltimore, Maryland, United States
University of Florida COllege of Medicine/Shands Cancer Center
🇺🇸
Gainesville, Florida, United States
Vanderbilt University Medical Center
🇺🇸
Nashville, Tennessee, United States
Lombardi Comprehensive Cancer Center, Georgetown University Hospital
🇺🇸
Washington, District of Columbia, United States
Florida Cancer Specialists
🇺🇸
Fort Myers, Florida, United States
Arizona Clinical Research Center
🇺🇸
Tucson, Arizona, United States
Sarah Cannon Research Institute
🇺🇸
Nashville, Tennessee, United States
University of Miami - Sylvester Comprehensive Cancer Center
🇺🇸
Miami, Florida, United States
Clearview Cancer Institute
🇺🇸
Huntsville, Alabama, United States
USC/Norris Comprehensive Cancer Center
🇺🇸
Los Angeles, California, United States
NYU Clinical Trials Office, New York University Cancer Institute
🇺🇸
New York, New York, United States